Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lumos Diagnostics Holdings Limited specializes in point-of-care diagnostic testing, particularly in the areas of infectious diseases and chronic conditions. Its proprietary technology, including the Lumos platform, allows for rapid and accurate testing, primarily targeting markets in Australia and the United States. The company's competitive edge lies in its innovative product offerings and partnerships with healthcare providers.
Lumos generates revenue through the sale of its diagnostic testing products, leveraging its proprietary technology to offer rapid results that meet the needs of healthcare providers. The company benefits from high gross margins due to the low cost of production relative to pricing, which is supported by its unique technology and established partnerships.
Regulatory approvals for new diagnostic tests
Partnership announcements with healthcare providers
Market adoption rates of point-of-care testing
Changes in healthcare policies affecting diagnostic testing
Technological disruption from competitors developing faster or cheaper diagnostic solutions
Regulatory changes that could impact the approval process for new tests
Emerging competitors in the point-of-care testing space
Price competition from established diagnostic companies
High debt-to-equity ratio (2.26) raises concerns about financial stability
Negative operating cash flow could limit operational flexibility
moderate - The demand for diagnostic testing can be influenced by overall healthcare spending, which is tied to GDP growth and consumer spending patterns.
Interest rates affect Lumos primarily through the cost of financing for operations and R&D. Higher rates could increase borrowing costs, impacting cash flow and investment in growth initiatives.
minimal - The company does not heavily rely on credit for its operations, but high debt levels could pose risks if cash flows do not improve.
growth - Investors are likely attracted to Lumos for its potential in the rapidly expanding point-of-care diagnostics market.
high - The stock has shown significant volatility, evidenced by a 250% return over the past year, but also a 68.4% decline over the past six months.
